The mix-up in labels can cause either overdosing or underdosing in patients who unknowingly take the wrong dose. Digoxin is used to treat patients with heart failure and chronic atrial fibrillation.
Marlex Pharmaceuticals is recalling one lot of Digoxin Tablets, 0.125 mg and one lot of Digoxin Tablets, 0.25 mg to because of a label mix-up. Bottles of digoxin 0.125 mg are incorrectly labeled and contain digoxin 0.25 mg tablets. Bottles of digoxin 0.25 mg are incorrectly labeled and contain digoxin 0.125 mg.
Digoxin is used to treat patients with mild-to-moderate heart failure and chronic atrial fibrillation. The mix-up in labels can cause either overdosing or underdosing in patients who unknowingly take the wrong dose. Patients who unknowingly digoxin 0.25 mg would receive a super potent dose and can experience significant drug toxicity (mental disorientation, dizziness, blurred vision, memory loss and fainting) from the unintentional overdose. Patients who unknowingly take digoxin 0.125mg would receive a sub potent dose which may lead to loss of control of heart rate and potential heart failure exacerbation.
Marlex Pharmaceuticals has not received any reports of adverse events related to this recall.
The two lots involved in the recall (labels below):
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More